SOLENO THERAPEUTICS ($SLNO) posted quarterly earnings results on Wednesday, May 7th. The company reported earnings of -$0.95 per share, missing estimates of -$0.95 by $0.00. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $SLNO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SOLENO THERAPEUTICS Insider Trading Activity
SOLENO THERAPEUTICS insiders have traded $SLNO stock on the open market 84 times in the past 6 months. Of those trades, 0 have been purchases and 84 have been sales.
Here’s a breakdown of recent trading of $SLNO stock by insiders over the last 6 months:
- OPPORTUNITY, LLC VIVO has made 0 purchases and 3 sales selling 1,833,557 shares for an estimated $124,449,124.
- BHATNAGAR ANISH (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 15 sales selling 720,186 shares for an estimated $48,237,475.
- PATRICIA C HIRANO (SEE REMARKS) has made 0 purchases and 20 sales selling 163,127 shares for an estimated $11,113,218.
- JAMES H MACKANESS (CHIEF FINANCIAL OFFICER) has made 0 purchases and 14 sales selling 98,496 shares for an estimated $6,653,637.
- KRISTEN YEN (SEE REMARKS) has made 0 purchases and 13 sales selling 100,360 shares for an estimated $6,599,272.
- MEREDITH MANNING (Chief Commercial Officer) has made 0 purchases and 9 sales selling 45,249 shares for an estimated $3,044,342.
- MICHAEL F. HUANG (Sr. VP of Clinical Development) has made 0 purchases and 9 sales selling 14,583 shares for an estimated $1,013,627.
- MATTHEW PAULS sold 5,937 shares for an estimated $424,797
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SOLENO THERAPEUTICS Hedge Fund Activity
We have seen 131 institutional investors add shares of SOLENO THERAPEUTICS stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CARLYLE GROUP INC. removed 2,695,916 shares (-66.2%) from their portfolio in Q4 2024, for an estimated $121,181,424
- PERCEPTIVE ADVISORS LLC removed 1,703,936 shares (-53.2%) from their portfolio in Q4 2024, for an estimated $76,591,923
- JANUS HENDERSON GROUP PLC added 1,107,166 shares (+27.1%) to their portfolio in Q4 2024, for an estimated $49,767,111
- CITADEL ADVISORS LLC added 950,670 shares (+4372.9%) to their portfolio in Q4 2024, for an estimated $42,732,616
- NANTAHALA CAPITAL MANAGEMENT, LLC added 658,518 shares (+20.1%) to their portfolio in Q4 2024, for an estimated $29,600,384
- ALYESKA INVESTMENT GROUP, L.P. removed 552,024 shares (-56.6%) from their portfolio in Q4 2024, for an estimated $24,813,478
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 546,170 shares (-16.4%) from their portfolio in Q4 2024, for an estimated $24,550,341
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SOLENO THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SLNO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 03/28/2025
- Laidlaw issued a "Buy" rating on 03/27/2025
- Cantor Fitzgerald issued a "Overweight" rating on 03/27/2025
- H.C. Wainwright issued a "Buy" rating on 12/02/2024
To track analyst ratings and price targets for SOLENO THERAPEUTICS, check out Quiver Quantitative's $SLNO forecast page.
SOLENO THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $SLNO recently. We have seen 4 analysts offer price targets for $SLNO in the last 6 months, with a median target of $91.5.
Here are some recent targets:
- Debjit Chattopadhyay from Guggenheim set a target price of $81.0 on 03/28/2025
- An analyst from Robert W. Baird set a target price of $102.0 on 03/27/2025
- An analyst from UBS set a target price of $105.0 on 03/27/2025
- Raghuram Selvaraju from H.C. Wainwright set a target price of $70.0 on 12/02/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
